WHO lists first Ebola Bundibugyo test as DRC cases hit 1,406

WHO listed the first molecular diagnostic test for Ebola Bundibugyo virus on 2 July 2026 as DRC cases reached 1,406.

For UAE healthcare executives, the practical issue is readiness for a suspected imported case: which lab pathway is approved, who notifies regulators, and whether isolation protocols still work in 2026.

What WHO listed

WHO added the molecular test to its Emergency Use Listing for in vitro diagnostics on 2 July 2026. The test detects Bundibugyo virus genetic material in blood samples, according to WHO, and gives United Nations procurement agencies and national buyers a quality-assured option during the declared emergency.

Public health emergencies require speed, and confidence that health products meet standards for quality, safety and performance. During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission.

Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data

The listing followed a 17 May 2026 declaration by WHO Director-General Dr Tedros Adhanom Ghebreyesus of a public health emergency of international concern for Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo, with cases in Uganda. Less than two weeks later, WHO asked manufacturers of BDBV in vitro diagnostics to submit expressions of interest for Emergency Use Listing.

Why UAE operators should track it

Dubai Health Authority, Department of Health Abu Dhabi and Ministry of Health and Prevention facilities already operate within communicable disease surveillance, infection-control and reporting systems designed for imported disease risk. A WHO-listed test gives UAE hospital laboratories, emergency departments and executive teams a clearer procurement reference if referral testing, specimen transport or isolation procedures need fast review in 2026.

The outbreak also shows why test capacity changes operations. WHO and Africa Centres for Disease Control and Prevention reported that laboratory capacity in affected provinces expanded from mainly Institut National de Recherche Biomédicale sites in Kinshasa and Goma, with an estimated 200 to 400 tests per day, to 10 laboratories with reported capacity above 2,000 tests per day.

• COOs should review isolation-room access, emergency department triage scripts and specimen transport procedures in 2026.
• CIOs should check whether hospital information systems can flag suspected Ebola through travel history, exposure risk, lab orders and reportable disease workflows.
• Medical directors should refresh clinician guidance for fever, travel history, exposure risk and escalation to infection prevention teams.
• CFOs should watch whether WHO-listed tests enter regional procurement channels, because emergency diagnostics can create unplanned laboratory and stockholding costs.

Procurement signals to watch

Bundibugyo virus disease is one of 3 Ebola virus species known to cause large outbreaks in humans, according to WHO. The virus can pass from animals to humans and then between people through infected bodily fluids, contaminated surfaces or contaminated items, which makes front-door recognition and laboratory escalation more relevant for UAE providers than broad routine screening.

WHO said more BDBV in vitro diagnostic applications are under review as of 2 July 2026. WHO is also working with Africa CDC, PATH, FIND, CHAI and Unitaid on a validation platform for laboratory molecular tests, near-point-of-care molecular tests and antigen rapid diagnostic tests.

The number to remember is 1,406 confirmed cases. The action item for 2026 is narrower: confirm who owns suspected viral haemorrhagic fever escalation, which laboratory pathway is approved, and whether the electronic record can capture travel and exposure data without manual workarounds. If cases spread beyond DRC and Uganda, those details will decide whether UAE facilities lose hours at triage, in the laboratory or during regulator notification.